ATE295369T1 - Pharmazeutika zur bildgebung der angiogenischen krankheiten - Google Patents

Pharmazeutika zur bildgebung der angiogenischen krankheiten

Info

Publication number
ATE295369T1
ATE295369T1 AT99941944T AT99941944T ATE295369T1 AT E295369 T1 ATE295369 T1 AT E295369T1 AT 99941944 T AT99941944 T AT 99941944T AT 99941944 T AT99941944 T AT 99941944T AT E295369 T1 ATE295369 T1 AT E295369T1
Authority
AT
Austria
Prior art keywords
pharmaceuticals
angiogenic diseases
imaging angiogenic
imaging
diseases
Prior art date
Application number
AT99941944T
Other languages
English (en)
Inventor
Miland Rajopadhye
D Scott Edwards
Thomas D Harris
Stuart J Heminway
Shuang Liu
Prahlad R Singh
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Application granted granted Critical
Publication of ATE295369T1 publication Critical patent/ATE295369T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
AT99941944T 1998-03-31 1999-03-29 Pharmazeutika zur bildgebung der angiogenischen krankheiten ATE295369T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8015098P 1998-03-31 1998-03-31
US11271598P 1998-12-18 1998-12-18
PCT/US1999/006826 WO1999058162A2 (en) 1998-03-31 1999-03-29 Pharmaceuticals for the imaging of angiogenic disorders

Publications (1)

Publication Number Publication Date
ATE295369T1 true ATE295369T1 (de) 2005-05-15

Family

ID=26763137

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99941944T ATE295369T1 (de) 1998-03-31 1999-03-29 Pharmazeutika zur bildgebung der angiogenischen krankheiten

Country Status (20)

Country Link
US (2) US6322770B1 (de)
EP (1) EP1068224B1 (de)
JP (1) JP4487019B2 (de)
KR (1) KR20010042288A (de)
CN (1) CN1295578A (de)
AR (1) AR020586A1 (de)
AT (1) ATE295369T1 (de)
AU (1) AU5541799A (de)
BR (1) BR9909420A (de)
CA (1) CA2324555A1 (de)
DE (1) DE69925262T2 (de)
EA (1) EA200001007A1 (de)
EE (1) EE200000574A (de)
ES (1) ES2241313T3 (de)
HU (1) HUP0101468A2 (de)
IL (1) IL138093A0 (de)
NO (1) NO20004917L (de)
PL (1) PL343804A1 (de)
SK (1) SK13952000A3 (de)
WO (1) WO1999058162A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6794518B1 (en) * 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6989139B2 (en) * 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
JP2003532877A (ja) * 2000-05-08 2003-11-05 アンテルユニヴェルシテール・ミクロ−エレクトロニカ・サントリュム・ヴェー・ゼッド・ドゥブルヴェ ハイスループットリードプロファイリング方法
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
CA2410887C (en) 2000-06-02 2012-07-24 Bracco Research Usa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
AU2001268710A1 (en) * 2000-06-21 2002-01-02 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
AU2001270025B2 (en) * 2000-06-21 2005-08-18 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
EP1311301A2 (de) * 2000-07-06 2003-05-21 Bristol-Myers Squibb Pharma Company Stabile radiopharmazeutische formulierungen
CA2429956A1 (en) 2000-11-27 2002-07-18 Alan P. Carpenter, Jr. Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
US7271180B2 (en) * 2001-01-23 2007-09-18 Wyeth 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
EP1381396B1 (de) 2001-04-23 2009-04-01 Mallinckrodt Inc. Tc und re markierte radioaktive glycosylierte octreotid-derivate
WO2003013346A2 (en) * 2001-08-08 2003-02-20 Bristol-Myers Squibb Pharma Company Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
CN100560131C (zh) 2001-10-22 2009-11-18 斯克里普斯研究学院 抗体靶向化合物
BR0307206A (pt) * 2002-01-24 2004-12-21 Barnes Jewish Hospital Agentes de formação de imagem direcionados por integrina
US7279150B2 (en) 2002-01-24 2007-10-09 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US7666979B2 (en) 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US7985402B2 (en) 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
CA2513044A1 (en) * 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
EP2301587B1 (de) * 2002-03-01 2014-06-25 Dyax Corp. KDR- und VEGF/KDR-bindende Peptide sowie ihre Verwendung bei der Diagnose und Therapie
ATE535009T1 (de) * 2002-05-08 2011-12-15 Phoseon Technology Inc Hocheffiziente halbleiter-lichtquelle sowie verfahren zu deren verwendung und herstellung
US6961607B2 (en) * 2002-07-31 2005-11-01 Uzgiris Egidijus E Method for assessing myocardial angiogenesis
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
WO2004022153A2 (en) * 2002-09-05 2004-03-18 Genentech, Inc. Infusion catheter having an integrated doppler transducer
US20040047917A1 (en) * 2002-09-06 2004-03-11 Stephen Wilson Drug delivery and targeting with vitamin B12 conjugates
DE60310958T2 (de) * 2002-09-19 2007-10-11 Centre National De La Recherche Scientifique (Cnrs) Synthese und charakterisierung neuer systeme zum hinführen und zur vektorisierung von molekülen von therapeutischem interesse zu targetzellen
WO2004069281A1 (en) * 2003-01-30 2004-08-19 The General Hospital Corporation Bifunctional molecules comprising at least one integrin-binding and their use in imaging and therapy of angiogenesis and related disorders
CA2517939C (en) 2003-03-03 2015-11-24 Dyax Corp. Peptides that specifically bind hgf receptor (cmet) and uses thereof
CA2525396A1 (en) * 2003-05-12 2004-11-25 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist compounds and their use in the preparation of radiopharmaceuticals
CA2534426A1 (en) * 2003-08-08 2005-02-17 Barnes-Jewish Hospital Emulsion particles for imaging and therapy and methods of use thereof
US20050112064A1 (en) * 2003-08-12 2005-05-26 Sonya Franklin DNA-dependent MRI contrast agents
CA2559889A1 (en) * 2004-01-16 2005-08-25 Barnes-Jewish Hospital Targeted atherosclerosis treatment
JP2007523248A (ja) * 2004-02-23 2007-08-16 ダウ グローバル テクノロジーズ インコーポレイティド 低表面エネルギー基体接着用水性接着剤
AU2005253962A1 (en) 2004-06-09 2005-12-29 Kereos, Inc. Lipophilic derivatives of chelate monoamides
EP1612529B1 (de) * 2004-07-02 2007-04-11 Vivactis NV Messung der Wärme erzeugt durch einen chemischen oder biologischen Prozess.
JP2008538204A (ja) * 2005-03-10 2008-10-16 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 安定化側鎖を含む放射性標識複合体キレート剤
WO2006119013A2 (en) * 2005-04-29 2006-11-09 Wyeth Nogo receptor functional motifs and peptide mimetics related thereto and methods of using the same
WO2007048127A2 (en) * 2005-10-20 2007-04-26 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
WO2007070827A2 (en) * 2005-12-15 2007-06-21 Bristol-Myers Squibb Pharma Company Contrast agents for myocardium perfusion imaging
AU2007244705A1 (en) * 2006-04-27 2007-11-08 Barnes-Jewish Hospital Detection and imaging of target tissue
AU2007303465A1 (en) * 2006-09-29 2008-04-10 Washington University Combinations for treatment of neovasculature
WO2008073842A1 (en) * 2006-12-08 2008-06-19 Molecular Image Inc. Methods for diagnosis and monitoring of neurologic diseases using magnetic resonance methods
US8194963B2 (en) * 2008-03-10 2012-06-05 Siemens Medical Solutions Usa, Inc. Efficient estimator of pharmacokinetic parameters in breast MRI
KR20140001257A (ko) 2008-05-13 2014-01-06 유니버시티 오브 캔사스 금속 추출 펩타이드(ｍａｐ) 태그 및 관련된 방법
US20100178245A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
US8518927B2 (en) 2009-02-10 2013-08-27 The Scripps Research Institute Chemically programmed vaccination
CN101659694B (zh) * 2009-05-06 2012-12-12 河北科技大学 抗肿瘤环五肽化合物及其制备方法
WO2013181461A2 (en) 2012-06-01 2013-12-05 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
WO2014160903A2 (en) * 2013-03-27 2014-10-02 Theranos, Inc. Biological sample processing
AU2014251388B2 (en) * 2013-04-12 2017-03-30 Evox Therapeutics Limited Therapeutic delivery vesicles
DE102013113156A1 (de) * 2013-11-28 2015-05-28 Freie Universität Berlin Verbindung und Verfahren zur selektiven Radiomarkierung von Polypeptiden mittels Festphasensynthese
KR102548998B1 (ko) * 2020-03-31 2023-06-29 재단법인 아산사회복지재단 혈전영상을 위한 방사성의약품 및 조성물

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
EP0086627B1 (de) 1982-02-12 1985-08-28 Unitika Ltd. Antikrebsmittel
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
IL91933A (en) 1988-10-11 1994-12-29 Univ Southern California Their immuno-bracelet and isophiles which are beneficial in increasing vascular permeability or blood supply to tumor or otherwise damaged tissue
WO1990005539A1 (en) 1988-11-14 1990-05-31 Brigham And Women's Hospital Antibodies specific for elam-1 and the use thereof
US5376356A (en) 1989-03-14 1994-12-27 Neorx Corporation Imaging tissue sites of inflammation
WO1990012585A1 (en) 1989-04-10 1990-11-01 Oncogen Limited Partnership Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m
US5395609A (en) 1989-06-19 1995-03-07 Antisoma Limited Synthetic peptides for use in tumor detection
AU638043B2 (en) 1989-07-20 1993-06-17 Novartis Ag Labeled polypeptide derivatives
IN172208B (de) 1990-04-02 1993-05-01 Sint Sa
AU2861692A (en) 1991-10-18 1993-05-21 Beth Israel Hospital Association, The Vascular permeability factor targeted compounds
ES2193143T3 (es) 1992-03-05 2003-11-01 Univ Texas Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5342757A (en) 1992-11-13 1994-08-30 Ludwig Institute For Cancer Research Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof
CN1173991C (zh) 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
DE4301871A1 (de) 1993-01-13 1994-07-14 Diagnostikforschung Inst Neue Mittel zur Diagnose von Gefäßerkrankungen
US5744120A (en) 1993-03-30 1998-04-28 The Dupont Merick Pharmaceutical Company Ternary radiopharmaceutical complexes
DE4311023C2 (de) 1993-03-31 1996-05-02 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner von Typ XN¶1¶S¶1¶O¶1¶ für radioaktive Isotope, deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
ES2114209T3 (es) 1993-07-19 1998-05-16 Resolution Pharm Inc Queladores de radionuclidos de tipo hidrazino que tienen una configuracion n3s.
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
EP0762882A4 (de) 1994-06-29 2002-09-11 Smithkline Beecham Corp Vibronectin-rezeptor-antagonisten
DE69519929T2 (de) 1994-07-11 2001-05-23 Univ Texas Verfahren und zusammensetzungen für die spezifische koagulation von tumorgefässen
ATE203234T1 (de) 1995-08-30 2001-08-15 Searle & Co Meta-guanidine, harnstoff, thioharnstoff oder azacyklische aminobenzoesäure-derivate als integrin antagonisten
DE19536785A1 (de) 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ S¶2¶NY für radioaktive Isotope
DE19536781A1 (de) 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ XSNS für radioaktive Isotope
DE69628731T3 (de) * 1995-11-01 2012-09-20 Bracco Suisse S.A. Gezielte magnetisch markierte molekularmarkersysteme als nmr-bilderzeugungsmittel
HUP0201479A2 (en) 1995-11-14 2002-08-28 Bristol Myers Squibb Pharma Co Novel macrocyclic compounds as metalloprotease inhibitors and pharmaceutical compositions containing them
US6331285B1 (en) * 1996-06-05 2001-12-18 Palatin Technologies, Inc. Structurally determined cyclic metallo-constructs and applications
ZA978758B (en) * 1996-10-02 1999-03-30 Du Pont Merck Pharma Technetium-99m-labeled chelator incorporated cyclic peptides that bind to the GPIIb/IIIa receptor as imaging agents
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
AU4753997A (en) * 1996-10-16 1998-05-11 Burnham Institute, The Magnetic resonance imaging of thrombi
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
EP0946202B1 (de) 1996-10-28 2003-09-10 Amersham Health AS Kontrastmittel
DE19725368A1 (de) * 1997-06-16 1998-12-17 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren und deren Verwendung für bildgebende Verfahren
DE69839844D1 (de) * 1997-09-10 2008-09-18 Burnham Inst Verfahren zur auffindung von zielsuchenden verbindungen spezifisch für angiogenese vaskulatur
EP1056773A2 (de) * 1998-02-11 2000-12-06 Resolution Pharmaceuticals Inc. Für angiogenese spezifische moleküle
CA2338275A1 (en) 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists

Also Published As

Publication number Publication date
CA2324555A1 (en) 1999-11-18
JP4487019B2 (ja) 2010-06-23
KR20010042288A (ko) 2001-05-25
CN1295578A (zh) 2001-05-16
PL343804A1 (en) 2001-09-10
ES2241313T3 (es) 2005-10-16
AU5541799A (en) 1999-11-29
EP1068224B1 (de) 2005-05-11
US20020001566A1 (en) 2002-01-03
WO1999058162A3 (en) 2000-04-06
AR020586A1 (es) 2002-05-22
NO20004917D0 (no) 2000-09-29
HUP0101468A2 (hu) 2001-08-28
JP2002514611A (ja) 2002-05-21
WO1999058162A2 (en) 1999-11-18
NO20004917L (no) 2000-11-02
IL138093A0 (en) 2001-10-31
BR9909420A (pt) 2001-09-25
EP1068224A2 (de) 2001-01-17
EE200000574A (et) 2002-10-15
DE69925262D1 (de) 2005-06-16
SK13952000A3 (sk) 2001-12-03
DE69925262T2 (de) 2006-02-23
EA200001007A1 (ru) 2001-04-23
US6322770B1 (en) 2001-11-27

Similar Documents

Publication Publication Date Title
ATE295369T1 (de) Pharmazeutika zur bildgebung der angiogenischen krankheiten
NO992339L (no) Farmasöytiske formuleringer
DE69919028D1 (de) Biegbarer katheter zur bildgebung
DE69942437D1 (de) Verbessertes System zur intraluminalen Bildgebung
IS5953A (is) Lyfjablöndur úr örgerðum eplerenonum
DE69819289D1 (de) Bildgeführtes chirurgisches system
DE60045264D1 (de) Fixationssystem
DE69936767D1 (de) Patientenmonitor
DE69805455D1 (de) Diagnostische Bilderzeugung
DE19880445D2 (de) Endoskopisches System
DE69830346D1 (de) Abbildungsgerät
NO20001093D0 (no) Spekulum
DE69939195D1 (de) Bilderzeugungsvorrichtung
DE69942004D1 (de) Bildaufnahmevorrichtung
DK1466615T3 (da) Farmaceutisk præparat
FR2765349B1 (fr) Endoscope
DE59800089D1 (de) Laryngoskop
ATE309838T1 (de) Pharmazeutisches implantat
DE69905931T2 (de) Bankautomat zur selbstbedienung
DE69821714D1 (de) Bilderzeugungsverfahren
ID30032A (id) Formulasi farmasi
DE69813131T2 (de) Bilderzeugungsverfahren
DE60017700D1 (de) Bildgebungsverfahren
NO20020076D0 (no) Impulskjöps-system for betalings-TV
DE60029285D1 (de) Gerät zur Bildanalyse

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties